Fiorentino, F., Canali, B., Morelli, P., & Demma, F. (2023). Brentuximab vedotin in combination with doxorubicin, vinblastine and dacarbazine for first-line treatment of stage IV HL: cost impact on subsequent lines in Italy. AboutOpen, 10(1), 6–12. https://doi.org/10.33393/ao.2023.2486